Lu AE58054 (Alzheimer’s Disease)：市場予測と分析（～2022）...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 8
1.2 List of Figures 9
2 Introduction 10
2.1 Catalyst 10
2.2 Related Reports 11
3 Disease Overview 13
3.1 Etiology and Pathophysiology 14
3.1.1 Etiology 14
3.1.2 Pathophysiology 17
3.2 Symptoms 29
4 Disease Management 31
4.1 Diagnosis 31
4.1.1 Probable Alzheimer’s Disease Dementia 32
4.1.2 Possible AD Dementia 33
4.1.3 Probable AD Dementia with Evidence of AD Pathophysiological Process 33
4.1.4 Possible Alzheimer’s Dementia with Evidence of the Alzheimer’s Disease Pathophysiological Process 34
4.1.5 Preclinical AD 34
4.1.6 Mild Cognitive Impairment 35
4.2 Treatment Overview 37
5 Competitive Assessment 40
5.1 Overview 40
5.2 Strategic Competitor Assessment 40
6 Opportunity and Unmet Need 43
6.1 Unmet Needs Overview 43
6.1.1 Public Awareness 45
6.1.2 Specialized Institutions at Local Levels 46
6.1.3 Screening and Diagnosis 46
6.1.4 Early Intervention 47
6.1.5 Improved Clinical Trial Design 48
6.1.6 Effective Therapy 49
6.1.7 Behavioral Treatments 50
6.2 Gap Analysis 50
6.2.1 Disease Prevention 51
6.2.2 Diagnosis from Biomarkers 52
6.2.3 Behavioral Therapies 53
7 Pipeline Assessment 54
7.1 Overview 54
7.2 Early-Stage Pipeline Assessment 55
7.3 AD Pipeline by Mechanism of Action 57
7.4 Enzymatic Processing 57
7.5 Immunization 58
7.6 Anti-Aggregation 59
7.7 “Me-Too” 59
7.8 Novel Therapeutic Approaches 60
7.9 Technology Trends Analytic Framework 61
7.10 Promising Drugs in Clinical Development 62
8 Lu AE58054 65
8.1 Overview 65
8.2 Efficacy 66
8.3 Safety 66
8.4 Dosing and Formulation 66
8.5 Potential Clinical Positioning 67
8.6 Potential Commercial Positioning 67
8.7 Pricing and Reimbursement 67
8.8 SWOT Analysis 68
8.9 Forecast 68
9 Appendix 69
9.1 Bibliography 69
9.2 Abbreviations 74
9.3 Methodology 77
9.4 Forecasting Methodology 77
9.4.1 Diagnosed AD patients 78
9.4.2 Percent Drug-treated Patients 78
9.4.3 General Pricing Assumptions 78
9.4.4 Generic Erosion 79
9.4.5 Pricing of Pipeline Agents 79
9.4.6 Alternate Scenarios 79
9.5 Physicians and Specialists Included in this Study 80
9.6 About the Authors 81
9.6.1 Author 81
9.6.2 Global Head of Healthcare 82
9.7 About GlobalData 83
9.8 Disclaimer 83